Biblio Discovery — Demo Discovery Service

7 hasil untuk "Adam, David N"

Menampilkan 1–7 · 0,21 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Spotlight on pembrolizumab in the treatment of advanced melanoma

    Rajakulendran, Thanashan; Adam, David N

    Drug Des Devel Ther · 2015 · Inggris · PubMed Central

    Metastatic melanoma is an aggressive cancer with a poor prognosis. Many approved therapies often do not achieve durable responses in patients. This underscores the need for novel therapeutic strategies. Recruiting a robust immune response is an important antineoplastic treatment strategy. Immune…

  2. Artikel Jurnal Teks lengkap

    A Rare Variant of a Common Nodule

    Xi, Nancy; Assaad, Dalal; Adam, David N.

    Mcgill J Med · 2011 · Inggris · PubMed Central

  3. Artikel Jurnal Teks lengkap

    Tinea Pedis Presenting as Asymmetric Purpuric Papules on the Sole of the Foot: A Case Report

    Chen, Jennifer Yan Fei; Stroz, Marianne J.; Adam, David N.

    Case Rep Dermatol · 2015 · Inggris · PubMed Central

    In this report we describe a unique case of tinea pedis. A 29-year-old man presented with a 3-day history of asymptomatic purpuric papules predominantly on his left foot. Potassium hydroxide preparation demonstrated fungal hyphae and culture yielded Trichophyton mentagrophytes. This patient…

  4. Artikel Jurnal Teks lengkap

    Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis

    Adam, David N.; Jablonski Bernasconi, Marie Y.; Thoning, Henrik dkk.

    Dermatol Ther (Heidelb) · 2022 · Inggris · PubMed Central

    INTRODUCTION: To date, there have been no head-to-head clinical studies comparing calcipotriol 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam and halobetasol propionate 0.01% plus tazarotene 0.045% (HP/Taz) lotion for the treatment of plaque psoriasis. However, the efficacy of…

  5. Artikel Jurnal Teks lengkap

    Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis

    Silverberg, Jonathan I.; Adam, David N.; Zirwas, Matthew dkk.

    Am J Clin Dermatol · 2022 · Inggris · PubMed Central

    BACKGROUND: The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were evaluated over 32 weeks in the phase III ECZTRA 3 trial. Significantly more tralokinumab- versus placebo-treated…

  6. Artikel Jurnal Teks lengkap

    Practical Management of Patients with Atopic Dermatitis on Dupilumab

    Papp, Kim A.; Hong, Chih-ho; Lansang, M. Perla dkk.

    Dermatol Ther (Heidelb) · 2021 · Inggris · PubMed Central

    INTRODUCTION: Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particular interest in transitioning from current…

  7. Artikel Jurnal Teks lengkap

    Optimizing the management of psoriasis in patients with skin of color: A Canadian Delphi consensus

    Yadav, Geeta; Miller-Monthrope, Yvette; Rao, Jaggi dkk.

    JAAD Int · 2024 · Inggris · PubMed Central

    BACKGROUND: There is limited evidence on treating psoriasis patients with skin of color (SOC), contributing to disparities in accessing appropriate care for these patients. OBJECTIVES: This study aimed to develop consensus statements defining SOC terminology and addressing needs to optimize the…